Professor & Chair., Department of Dermatology at Case Western, Reserve University and University Hospitals ,Case Medical Center
Scientifically, my interests lie in monocyte and T cell-lineage mechanisms of skin inflammation and its regulation, and in clinical translation for photomedicine applications, psoriasis, cutaneous T cell lymphomas, dermatitis, and skin cancers. More broadly, through my role as chair and other leadership opportunities, my career is focused on advancing the understanding and treatment of skin diseases, and on mentoring others to become effective contributors to this area. My role as Director of the Skin Diseases Research Center (SDRC) and its Administrative Core is a fully-aligned match with my personal goals and skill sets, in that the SDRC’s goals are to develop and promote skin-centered research by focusing new basic findings and technologies on skin disease applications. My broad dermatologic investigational experience and institutional resource awareness is well utilized in promoting communication and interdisciplinary interactions among SDRC investigators, as well as overseeing the Enrichment programs, in particular, the Pilot and Feasibility Program. Similarly, my financial, administrative and scientific experience benefits the directors of the Core laboratories in organizing proper governance of the cores and optimizing service to the Center membership base. My med-sci organizational leadership capabilities are recognized through election as President of the UH Case Medical Center/Case Western Reserve University Council of Clinical Chairs of the Association of Professors of Dermatology, and of the Society for Investigative Dermatology (04-05). I am currently the Chairman of the National Psoriasis Foundation’s Scientific Advisory Committee, and past chair of basically the same committee for National Eczema Association. I have effectively administered clinical programs, teaching/training programs, a clinical laboratory program, clinical trials, multidisciplinary research, and translational initiatives for many years. My appointments to multiple key institutional research-related committees allow an excellent view of the opportunities for skin research at this academic medical center, as well as opportunities for SDRC advocacy.
Kevin D. Cooper, M.D. joined Case Western Reserve University and University Hospitals Case Medical Center in 1995 from prior positions at the University of Michigan and the National Institutes of Health, following training at Oregon Health Sciences University and the University of Florida. He has developed a highly matrixed department that intersects nine geographical clinical dermatology practice sites with teaching, skin biology-specific research cores, and a complementary portfolio of research programs that span basic laboratory, translational, and clinical trial investigations. With interests in inflammatory-mediated skin diseases, lymphoma, and photomedicine/photoimmunology, Dr. Cooper has been continuously federally funded since 1986 and has published over 300 papers and chapters. He enjoys mentoring faculty, residents, fellows, and students across each of these dimensions.
Dr. Cooper is the Professor and Chair of the Department of Dermatology at both Case Western Reserve University (CWRU) School of Medicine and University Hospitals Case Medical Center (UHCMC) in Cleveland, Ohio. He is a Staff Physician for the Dermatology Service at the Cleveland VA Hospital. Dr. Cooper is the Director of the NIAMS Skin Diseases Research Center at CWRU, focusing on creating advances in skin diseases, and the Director of the Murdough Family Center for Psoriasis. He is Director of the NIAMS Psoriasis Center of Research Translation (CORT) at CWRU, performing lab-based, translational, and Phase I investigator – initiated clinical research where research team findings are moved from the “lab bench to the patient”. Dr. Cooper is a co-inventor of the first biologic to be FDA-approved for psoriasis, and he is a co-founder of Fluence Therapeutics, a start-up biomedical company created to develop a novel photodynamic therapy for psoriasis and lymphoma. He enjoys consulting in the early phases of product development for skin care and pharmaceuticals.